Double maintains 1 strategies that include MLYS - Mineralys Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PBE | 37.95% | $216.22M | 0.58% |
XBI | 36.80% | $4.86B | 0.35% |
XPH | 35.07% | $137.85M | 0.35% |
IBB | 34.97% | $5.30B | 0.45% |
ARKG | 30.59% | $975.88M | 0.75% |
PTH | 30.46% | $103.55M | 0.6% |
IWC | 30.42% | $728.12M | 0.6% |
GNOM | 30.35% | $47.00M | 0.5% |
BBH | 30.12% | $338.11M | 0.35% |
PINK | 30.06% | $135.92M | 0.5% |
FBT | 30.00% | $1.01B | 0.56% |
KAPR | 29.82% | $170.17M | 0.79% |
IWO | 28.75% | $10.38B | 0.24% |
EPHE | 28.65% | $95.41M | 0.59% |
PBW | 28.15% | $183.80M | 0.65% |
CALF | 28.01% | $4.19B | 0.59% |
IWM | 28.00% | $57.33B | 0.19% |
PID | 27.78% | $793.00M | 0.53% |
VTWO | 27.78% | $10.54B | 0.07% |
ANGL | 26.95% | $2.77B | 0.25% |
Yahoo
Key Insights Institutions' substantial holdings in Mineralys Therapeutics implies that they have significant influence...
Finnhub
Targeting Aldosterone in the Treatment of Cardiorenal Diseases April 2025 Mineralys: Targeting Aldosterone in the...
Yahoo
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – – Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor – – Data from Advance-HTN support the potential of lorundrostat as a best-in-class treatment for high-risk patients with uncontrolled or resi
Finnhub
Mineralys Therapeutics, Inc. announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat in patients with confirmed uncontrolled hypertension or...
Yahoo
We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stands against other stocks that are receiving the most insider investment in March. “The economy is strong overall and has made significant progress toward […]
Yahoo
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertensionRADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will ho
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RKT | -19.92% | $1.84B | +13.75% | 0.00% |
K | -15.48% | $28.41B | +46.76% | 2.76% |
STG | -14.56% | $24.34M | -44.42% | 0.00% |
CLX | -12.93% | $16.85B | -3.89% | 3.48% |
PULM | -12.72% | $20.14M | +163.88% | 0.00% |
VHC | -12.07% | $36.41M | +51.37% | 0.00% |
BTCT | -11.23% | $16.73M | +20.22% | 0.00% |
FAT | -8.69% | $43.24M | -38.57% | 17.00% |
NPWR | -8.46% | $164.14M | -79.62% | 0.00% |
KDP | -8.26% | $47.64B | +13.70% | 2.55% |
VSCO | -7.67% | $1.23B | -6.75% | 0.00% |
RLX | -7.55% | $1.62B | -5.62% | 0.59% |
CNC | -7.43% | $30.75B | -13.92% | 0.00% |
COKE | -7.37% | $12.20B | +72.48% | 0.42% |
LFVN | -6.96% | $178.04M | +114.92% | 1.09% |
FLUT | -6.89% | $40.15B | +25.31% | 0.00% |
FICO | -6.49% | $46.39B | +64.73% | 0.00% |
BRBR | -6.36% | $9.48B | +36.08% | 0.00% |
APP | -5.96% | $78.13B | +224.13% | 0.00% |
ANGO | -5.81% | $384.14M | +49.45% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PTGX | 53.88% | $2.81B | +79.12% | 0.00% |
RDFN | 45.17% | $1.10B | +62.41% | 0.00% |
VRN | 34.34% | $3.65B | -29.96% | 5.53% |
OUST | 33.56% | $371.52M | -2.40% | 0.00% |
OCUL | 33.26% | $1.14B | -5.41% | 0.00% |
KOD | 33.09% | $124.49M | -34.44% | 0.00% |
APGE | 32.88% | $1.91B | -37.79% | 0.00% |
CRNX | 32.85% | $2.75B | -32.79% | 0.00% |
KN | 32.15% | $1.25B | -8.12% | 0.00% |
CELC | 32.08% | $378.02M | -41.27% | 0.00% |
ORA | 32.02% | $4.26B | +13.27% | 0.68% |
ACLX | 31.55% | $3.33B | +13.33% | 0.00% |
ASGN | 31.29% | $2.60B | -37.42% | 0.00% |
INMD | 31.14% | $1.04B | -14.56% | 0.00% |
ALB | 30.98% | $6.18B | -54.04% | 3.03% |
IOVA | 30.97% | $1.01B | -73.98% | 0.00% |
XNCR | 30.60% | $670.80M | -50.08% | 0.00% |
KRYS | 30.25% | $4.76B | -2.91% | 0.00% |
RCKT | 30.19% | $655.77M | -74.03% | 0.00% |
REGN | 29.98% | $60.05B | -39.05% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBMF | 0.12% | $1.13B | 0.85% |
CMBS | 0.24% | $425.50M | 0.25% |
ULST | -0.25% | $624.74M | 0.2% |
YOLO | 0.34% | $21.46M | 1.12% |
MMIT | -0.36% | $819.88M | 0.3% |
FMHI | -0.42% | $736.03M | 0.7% |
TPMN | -0.50% | $31.19M | 0.65% |
SMB | -0.54% | $263.52M | 0.07% |
SOYB | 0.59% | $25.45M | 0.22% |
IVOL | 0.64% | $313.84M | 1.02% |
BWZ | 0.75% | $207.18M | 0.35% |
BSMR | 0.85% | $235.24M | 0.18% |
HTAB | -1.06% | $432.55M | 0.39% |
KMLM | -1.09% | $200.23M | 0.9% |
IBDQ | -1.12% | $3.15B | 0.1% |
IBTF | 1.25% | $2.17B | 0.07% |
CGSM | 1.31% | $643.03M | 0.25% |
LGOV | 1.42% | $687.30M | 0.67% |
UNG | 1.44% | $394.77M | 1.06% |
FTSD | -1.44% | $219.63M | 0.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DHT | 0.08% | $1.62B | -10.64% | 9.48% |
MGPI | -0.08% | $568.77M | -65.62% | 1.78% |
DSP | 0.10% | $804.62M | +41.67% | 0.00% |
MOH | -0.11% | $18.18B | -7.63% | 0.00% |
HCI | -0.14% | $1.57B | +32.71% | 1.08% |
IMXI | -0.15% | $368.13M | -43.64% | 0.00% |
LPLA | 0.16% | $24.48B | +18.11% | 0.39% |
XGN | 0.20% | $80.00M | +219.29% | 0.00% |
DPZ | -0.21% | $15.86B | -4.11% | 1.34% |
CENX | 0.21% | $1.46B | -9.82% | 0.00% |
PRGS | 0.23% | $2.41B | +10.83% | 0.61% |
KNTK | 0.27% | $2.64B | +12.46% | 7.01% |
AMT | 0.30% | $102.05B | +26.73% | 3.00% |
CASY | -0.31% | $16.98B | +47.92% | 0.41% |
SAM | 0.33% | $2.67B | -14.88% | 0.00% |
ARHS | 0.34% | $1.07B | -47.52% | 0.00% |
CQP | 0.35% | $29.53B | +30.78% | 5.37% |
KO | -0.36% | $308.48B | +22.51% | 2.72% |
AVNW | -0.36% | $215.12M | -48.92% | 0.00% |
CNP | 0.37% | $23.97B | +32.78% | 2.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -16.72% | $406.36M | 1.43% |
VIXY | -15.13% | $195.31M | 0.85% |
TAIL | -13.20% | $110.17M | 0.59% |
MSOS | -10.40% | $296.60M | 0.77% |
XHLF | -10.10% | $1.06B | 0.03% |
JMST | -10.03% | $3.45B | 0.18% |
EQLS | -9.88% | $4.99M | 1% |
SGOV | -9.70% | $43.33B | 0.09% |
BSMW | -9.48% | $101.63M | 0.18% |
TBLL | -8.56% | $2.55B | 0.08% |
FLMI | -7.26% | $596.94M | 0.3% |
BIL | -7.17% | $48.78B | 0.1356% |
UUP | -7.14% | $254.57M | 0.77% |
XBIL | -6.07% | $738.89M | 0.15% |
USDU | -5.23% | $215.45M | 0.5% |
BILS | -5.03% | $3.88B | 0.1356% |
BILZ | -4.78% | $812.28M | 0.14% |
CNBS | -4.35% | $67.47M | 0.77% |
FXY | -4.33% | $839.80M | 0.4% |
SHV | -3.41% | $22.87B | 0.15% |
Current Value
$13.521 Year Return
Current Value
$13.521 Year Return